📋 Indications & Clinical Dosage
*Treatment of post-menopausal osteoporosis to reduce risk of vertebral and hip fractures:*
Adult: 1 tab once weekly.
Children: Not recommended.
⛔ Contraindications
Renal impairment with GFR <35 ml/min, oesophageal abnormalities, stricture, achalasia or inability to remain upright for 30 min after dosing, hypocalcaemia.
⚠️ Precautions & Warnings
Active GI bleeding, atypical femoral fractures, duodenitis, dysphagia, exclude other causes of osteoporosis, gastritis, history (within 1 year) of ulcers, surgery of the upper gastro-intestinal tract, symptomatic oesophageal disease, ulcers, upper GI disorders. Treat hypocalcaemia or vitamin D deficiency first. Warn patient to report any symptoms such as difficulty in swallowing, retrosternal pain or worsening heartburn, and to discontinue immediately.
🔄 Drug Interactions
Calcium supplement, antacids, NSAID.
⚠️ Adverse Reactions / Side Effects
Abdominal distension and pain, constipation, diarrhoea, dyspepsia, flatulence, headache, oesophageal reactions (oesophagitis, oesophageal ulcers, oesophageal stricture and oesophageal erosions), regurgitation, musculoskeletal pain, episcleritis, erythema, gastritis, nausea, rash, scleritis, uveitis, vomiting. Rare: Atypical femoral fractures with long-term use, hypocalcaemia, osteonecrosis of the jaw, photosensitivity, severe skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, upper gastro-intestinal ulcers
🤰 Pregnancy & Lactation Safety
Pregnancy Risk:
Contraindicated
Lactation / Breastfeeding:
Contraindicated
📚 Official Regulatory & Clinical References
- Drug Regulatory Authority of Pakistan (DRAP): Drug Registration, S.R.O. Price Gazettes & National Essential Medicines List (NEML).
- World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index).
- Formulary Standards: British National Formulary (BNF) & Pakistan National Formulary (PNF) guidelines.